Moderna’s shares rise by 3%

Moderna has garnered attention from investors after the result of its research were made public.

One of the pharmaceutical companies that produce the COVID-19 vaccine, Moderna, recorded a 3% increase in its stock market price.

The uptrend of Moderna’s stocks was reportedly caused by research results that showed that the company’s COVID-19 vaccine shot is 100% effective in adolescents and teenagers between the ages of 12 — 18.

Moderna’s COVID-19 vaccine shot ranks closely behind Pfizer’s for its fast results in young people.

Moderna is working towards filing for an FDA approval that will allow the easy availability of the COVID-19 vaccine shots for young teenagers in preparation for the incoming school year.